This clinical trial is focused on studying the effects of a medication called Spravato, which is a nasal spray containing the active substance esketamine. The study is specifically looking at its use in treating bipolar disorder during depressive episodes, particularly in cases where the depression has not responded to other treatments. This condition is often referred to as treatment-resistant bipolar depression.
The purpose of the study is to evaluate how effective and safe Spravato is for patients with this type of depression. Participants in the study will use the nasal spray, and researchers will monitor their response to the treatment over a period of time. The study is designed to gather information on how well the medication works and to observe any side effects that may occur. This information will help determine if Spravato could be a viable treatment option for those who have not found relief with other medications.
Throughout the study, participants will be closely observed to ensure their safety and to track any changes in their symptoms. The study will also look at how well participants tolerate the medication, which means checking if they can continue using it without significant issues. The findings from this trial may lead to further research, including more extensive studies that compare Spravato to a placebo, to better understand its potential benefits and risks for people with treatment-resistant bipolar depression.
The Netherlands 
